07:00 , Oct 7, 2013 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) gained $0.37 to $10.96 last week after submitting an NDA to FDA for Zalviso sufentanil sublingual microtablet system to manage moderate to severe acute pain in a hospital setting....
00:17 , Oct 5, 2013 |  BC Extra  |  Financial News

NeoStem raises $35 million in follow-on

NeoStem Inc. (NASDAQ:NBS) raised $35 million through the sale of 5 million shares at $7 in a follow-on underwritten by Aegis Capital. NeoStem proposed the offering late Thursday, when its share price was $7.84. On...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Clinical News

AMR-001: Additional Phase I data

Additional data from 23 patients in an open-label Phase I trial showed that AMR-001 significantly improved mid-anterior left-ventricular circumferential strain determined by MRI at 3 months vs. baseline (p=0.03), with no further improvement at 6...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Clinical News

AMR-001: Phase II ongoing

NeoStem's Amorcyte LLC subsidiary said a DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase II PreSERVE AMI trial of AMR-001 based on interim and safety data. The trial is evaluating AMR-001 given 5-11 days...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Clinical News

AMR-001: Phase II started

NeoStem's Amorcyte LLC company began the double-blind, placebo-controlled, U.S. Phase II PreSERVE trial to evaluate AMR-001 given 5-11 days post-stent placement in about 160 patients diagnosed with an ST segment elevation myocardial infarction. NeoStem Inc....
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Amorcyte, NeoStem deal

NeoStem completed its acquisition of cardiovascular company Amorcyte in a stock deal. NeoStem plans to begin a Phase II trial of Amorcyte's lead candidate, AMR-001 , to treat acute myocardial infarctions (AMI) by 1Q12. AMR-001...
00:35 , Oct 4, 2011 |  BC Extra  |  Financial News

Aspire Capital to buy up to $20M in NeoStem stock

Aspire Capital Fund agreed to purchase up to $20 million in NeoStem Inc. (NYSE-A:NBS) stock over a two-year period ending Sept. 30, 2013. Aspire will purchase shares at NeoStem's request, with the price set at...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Company News

Amorcyte, NeoStem deal

NeoStem will acquire cardiovascular company Amorcyte in a stock deal valued at $9.8 million based on NeoStem's closing price of $1.44 on July 13, before the deal was announced. Amorcyte shareholders will receive 6.8 million...
00:21 , Jul 20, 2011 |  BC Extra  |  Financial News

NeoStem raises $16.5M

Cell therapy company NeoStem Inc. (NYSE-A:NBS) raised $16.5 million through the sale of 13.8 million units at $1.20 in a follow-on underwritten by Lazard; JMP; Morgan Joseph; TriArtisan; Maxim Group; and National Securities. Each unit...
07:00 , Apr 6, 2009 |  BC Week In Review  |  Clinical News

AMR-001: Phase I data

In an open-label Phase I trial in 31 patients who received stents to treat recent MI, doses of 10 or 15 million cells of AMR-001 (n=9) led to a significant improvement in resting perfusion rate...